There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associat...
Authors: Marie Viala, Akiko Chiba, Simon Thezenas, Laure Delmond, Pierre-Jean Lamy, Sarah L. Mott, Mary C. Schroeder, Alexandra Thomas and William Jacot
Although lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations is common in never smokers, one-third of the patients are ever-smokers. We aimed to investigate the effect of cumu...
Authors: In Ae Kim, Jong Sik Lee, Hee Joung Kim, Wan Seop Kim and Kye Young Lee
At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered to be immediately operable (i.e. resectable). Considering their poor overall survival (OS), only tumours wi...
Authors: Lilian Schwarz, Dewi Vernerey, Jean-Baptiste Bachet, Jean-Jacques Tuech, Fabienne Portales, Pierre Michel and Antonio Sa Cunha
The impact of sarcopenia on the prognosis of patients with hepatocellular carcinoma (HCC) who receive transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcathete...
In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination ch...
Authors: Johannes Betge, Jing Chi-Kern, Nadine Schulte, Sebastian Belle, Tobias Gutting, Elke Burgermeister, Ralf Jesenofsky, Martin Maenz, Ulrich Wedding, Matthias P. Ebert and Nicolai Haertel
A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a bendamu...
Authors: Therasa Kim, He Yun Choi, Hyun-Seo Lee, Sung-Hoon Jung, Jae-Sook Ahn, Hyeoung-Joon Kim, Je-Jung Lee, Hee-Doo Yoo and Deok-Hwan Yang
Approximately 900 children/adolescents are treated with radiotherapy (RT) every year in France. However, among the 80% of survivors, the cumulative incidence of long-term morbidity – including second malignanc...
Authors: Valérie Bernier-chastagner, Liza Hettal, Véronique Gillon, Laurinda Fernandes, Cécile Huin-schohn, Marion Vazel, Priscillia Tosti, Julia Salleron, Aurélie François, Elise Cérimèle, Sandrine Perreira, Didier Peiffert, Pascal Chastagner and Guillaume Vogin
The purpose of this case report is to describe a conjunctiva and eyelid Kaposi’s sarcoma (KS) as the initial manifestation of acquired immunodeficiency syndrome (AIDS), which led to the diagnosis of HIV infect...
Authors: Filipe Sousa Neves, Joana Braga, João Cardoso da Costa, Joaquim Sequeira and Sandra Prazeres
Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the best sequence of treatment. The objective of this ...
Authors: M. Amini-Adle, N. Khanafer, M. Le-Bouar, G. Duru, S. Dalle and L. Thomas
The aim of this study was to compare the efficacies of the XELOX and DOS regimens as preoperative chemotherapy in patients with locally advanced gastric cancer.
Authors: Yan Wang, Xi Cheng, Yue-hong Cui, Jun Hou, Yuan Ji, Yi-hong Sun, Zhen-bin Shen, Feng-lin Liu and Tian-shu Liu
Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of metastatic breast ca...
The advent of tyrosine kinase inhibitors (TKIs) has changed the treatment of RAI refractory, unresectable recurrent differentiated thyroid cancer (DTC), which was formerly treated with multidisciplinary remedies.
Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU...
Authors: Danielle C. Glassman, Randze L. Palmaira, Christina M. Covington, Avni M. Desai, Geoffrey Y. Ku, Jia Li, James J. Harding, Anna M. Varghese, Eileen M. O’Reilly and Kenneth H. Yu
To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast can...
Authors: Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Kei Kimizuka and Masafumi Kurosumi
No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytosta...
Authors: Alessandro Broccoli, Laura Nanni, Vittorio Stefoni, Claudio Agostinelli, Lisa Argnani, Michele Cavo and Pier Luigi Zinzani
This study was performed to examine the usefulness of combined androgen blockade (CAB) therapy with a gonadotropin-releasing hormone (GnRH) antagonist (CAB-antagonist therapy), instead of CAB therapy with GnRH...
In the intensity-modulated radiotherapy (IMRT) era, great improvement has been made in survival of nasopharyngeal carcinoma (NPC). The 7th edition of the International Union against Cancer/American Joint Commi...
Authors: Xing-Li Yang, Yan Wang, Shao-Bo Liang, Sha-Sha He, Dan-Ming Chen, Hai-Yang Chen, Li-Xia Lu and Yong Chen
Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated...
Authors: Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó and Gyula Ostoros
Resistance to preoperative radiotherapy is a major clinical problem in the treatment for locally advanced rectal cancer. The role of NDRG1 in resistance to ionizing radiation in rectal cancer has not been fully e...
Authors: Soon-Chan Kim, Young-Kyoung Shin, Ye-Ah Kim, Sang-Geun Jang and Ja-Lok Ku
High Dose Rate Brachytherapy (HDRB) boost is a well-established treatment for prostate cancer (PC). We describe the PROstate Multicentre External beam radioTHErapy Using Stereotactic boost (PROMETHEUS) study. ...
Authors: Matthew Richardson, Mark Sidhom, Sarah Gallagher, Mel Grand, David Pryor, Joseph Bucci, Lee Wilton, Sankar Arumugam, Sarah Keats and Jarad M. Martin
Little data exists predicting the resistance to actinomycin D (Act-D) single-agent for gestational trophoblastic neoplasia (GTN). The objective was to determine the overall success of pulse Act-D and the facto...
Authors: Lei Li, Xirun Wan, Fengzhi Feng, Tong Ren, Junjun Yang, Jun Zhao, Fang Jiang and Yang Xiang
The objectives of this study were to build a normal tissue complication probability (NTCP) model of radiation-induced hypothyroidism (RHT) for nasopharyngeal carcinoma (NPC) patients and to compare it with oth...
Authors: Ren Luo, Vincent W. C. Wu, Binghui He, Xiaoying Gao, Zhenxi Xu, Dandan Wang, Zhining Yang, Mei Li and Zhixiong Lin
Standard treatment for unresectable esophageal squamous cell carcinoma (ESCC) without distant metastasis is definitive chemoradiotherapy (dCRT), in which the incidence of esophageal fistula (EF) is reported to...
Hepatocellular carcinoma (HCC) is a frequent type of primary liver cancer, and its prevalence is increasing worldwide. Indeed, the underlying molecular mechanism is not well understood. Previous studies have s...
Authors: Amit Kumar Ram, Biju Pottakat and Balasubramaniyan Vairappan
Prospective trials have demonstrated the advantage of dose-escalated radiotherapy for the biochemical and clinical control of intermediate risk prostate cancer. Dose escalation improves outcomes but increases ...
Authors: David Pasquier, Emilie Bogart, François Bonodeau, Thomas Lacornerie, Eric Lartigau and Igor Latorzeff
While data from several studies over the last decade has demonstrated that introduction of immunologic checkpoint blockage therapy with anti-CTLA-4/PD-1 drugs leads to improved survival in metastatic melanoma ...
Authors: Marin A. McDonald, Parag Sanghvi, Julie Bykowski and Gregory A. Daniels
S-1 plus oxaliplatin(SOX) has been demonstrated to be effective and well tolerated for patients with metastatic gastric cancer. We conducted this phase II study to evaluate the feasibility of SOX as adjuvant c...
Authors: Guoxiu Wang, Jiuda Zhao, Yan Song, Wen Zhang, Yongkun Sun, Aiping Zhou, Jing Huang, Feng Du and Lin Yang
Choriocarcinoma is a rare malignant germ-cell tumour, most commonly found in adult women. It infrequently presents as spontaneous renal haemorrhage (SRH). Genital malformation and SRH secondary to choriocarcin...
Authors: Yi Li, Gang Chen, Han Chen, Shuang Wen, Chao-yu Xiong, Zi-yi Yang, Yun-xiao Zhu and Nathan Jeffreys
Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) has been a standard treatment option for locally advanced rectal cancer with improved local control. However, systemic recurrence...
Authors: Chang Woo Kim, Byung Mo Kang, Ik Yong Kim, Ji Yeon Kim, Sun Jin Park, Won Cheol Park, Ki Beom Bae, Byung-Noe Bae, Seong Kyu Baek, Seung Hyuk Baik, Gyung Mo Son, Yoon Suk Lee and Suk-Hwan Lee
Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAFV600 kinase approved in more than 90 countries, based on results obtained pri...
Authors: Lu Si, Xiaoshi Zhang, Zhen Xu, Qiudi Jiang, Lilian Bu, Xuan Wang, Lili Mao, Weijiang Zhang, Nicole Richie and Jun Guo
Gastric cancer is common in developing regions, and we hope to find out an economical but practical prognostic indicator. It was reported that pre-treatment peripheral neutrophil-to-lymphocyte ratio (NLR) and ...
Authors: Zhenhua Huang, Yantan Liu, Chen Yang, Xiaoyin Li, Changqie Pan, Jinjun Rao, Nailin Li, Wangjun Liao and Li Lin
A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic c...
Melanoma brain metastasis is associated with an extremely poor prognosis, with a median overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV melanoma has been significantl...
Authors: Elham Vosoughi, Jee Min Lee, James R. Miller, Mehdi Nosrati, David R. Minor, Roy Abendroth, John W. Lee, Brian T. Andrews, Lewis Z. Leng, Max Wu, Stanley P. Leong, Mohammed Kashani-Sabet and Kevin B. Kim
Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first e...
Authors: Aline Mähringer-Kunz, Arndt Weinmann, Irene Schmidtmann, Sandra Koch, Sebastian Schotten, Daniel Pinto dos Santos, Michael Bernhard Pitton, Christoph Dueber, Peter Robert Galle and Roman Kloeckner
This pilot trial aimed to study the feasibility and effects on quality of life (QOL) and well-being of short-term fasting (STF) during chemotherapy in patients with gynecological cancer.
Authors: Stephan P. Bauersfeld, Christian S. Kessler, Manfred Wischnewsky, Annette Jaensch, Nico Steckhan, Rainer Stange, Barbara Kunz, Barbara Brückner, Jalid Sehouli and Andreas Michalsen
Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensit...
Authors: Clizia Zichi, Marco Tampellini, Marcello Tucci, Cristina Sonetto, Chiara Baratelli, Maria P. Brizzi and Giorgio V. Scagliotti
Radiogenic angiosarcoma of the breast (RASB) is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized t...
Authors: Askin Dogan, Peter Kern, Beate Schultheis, Günther Häusler, Günther A. Rezniczek and Clemens B. Tempfer
5-Fluorouracil (5FU), Folinic acid (FA), and Oxaliplatin (FOLFOX) or 5FU, FA, and Irinotecan (FOLFIRI) are standard regimens for palliative chemotherapy of metastatic colon cancer. Since data showing the influ...
Authors: Stefan Munker, Michael Gerken, Petra Fest, Claudia Ott, Elisabeth Schnoy, Stefan Fichtner-Feigl, Philipp Wiggermann, Martin Vogelhuber, Wolfgang Herr, Christian Stroszczynski, Hans Jürgen Schlitt, Matthias Evert, Michael Reng, Monika Klinkhammer-Schalke and Andreas Teufel
The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of mole...
Authors: Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite and Elona Juozaityte
To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with small hepatocellular carcinoma(sHCC) who were ineligible for surgery or ablation therapies.
Authors: Tao Zhang, Jing Sun, Weiping He, Huan Li, Junjie Piao, Huijun Xu and Xuezhang Duan
Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line trea...
Authors: Seiji Ito, Yasuo Ohashi and Mitsuru Sasako
To identify the incidence, recurrence pattern and prognosis of brain metastases (BM) among women with metastatic triple negative breast cancer (mTNBC) treated consecutively at a single institution during a 7-y...
Authors: Jia Jin, Yu Gao, Jian Zhang, Leiping Wang, Biyun Wang, Jun Cao, Zhimin Shao and Zhonghua Wang
Volumetric-modulated arc therapy (VMAT) is a highly sophisticated linear accelerator-based treatment method, and allows dose rate-changing intensity modulation with gantry rotation. We report our clinical expe...
Authors: Yuri Jeong, Jinhong Jung, Byungchul Cho, Jungwon Kwak, Chiyoung Jeong, Jong Hoon Kim, Jin-hong Park, So Yeon Kim, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee and Sang Min Yoon
SMARCB1 (INI1) is a tumor-suppressor gene located at 22q11.2. Loss of SMARCB1 protein expression has been reported to be associated with atypical teratoid/rhabdoid tumors and malignant rhabdoid tumors of the kidn...
Authors: Kazushi Yoshida, Yutaka Fujiwara, Yasushi Goto, Takashi Kohno, Akihiko Yoshida, Koji Tsuta and Yuichiro Ohe
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. M...
Authors: Lu Xie, Wei Guo, Ye Wang, Taiqiang Yan, Tao Ji and Jie Xu
Treatment of recurrent nasopharyngeal carcinoma is a challenging clinical problem. We report the case of a 46 year old male showing excellent response and signs of immunostimulation following re-re-irradiation...
Authors: T. Finazzi, T. Rordorf, K. Ikenberg, G. F. Huber, M. Guckenberger and H. I. Garcia Schueler
Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource imp...
Authors: Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang and Ming Kuang
Recent studies have reported a relationship between prognosis and neutrophil-to-lymphocyte ratio (NLR) in patients with head and neck cancer (HNC). As the results are still controversial, we conducted a meta-a...
Authors: Yalian Yu, Hongbo Wang, Aihui Yan, Hailong Wang, Xinyao Li, Jiangtao Liu and Wei Li
Treatment of localized gastric cancer (LGC) consists of surgical resection followed by adjuvant treatment. Both chemoradiation (CRT) and chemotherapy (CT) regimens have shown benefit in survival outcomes versu...
Authors: Daniel M. Girardi, Mariana A. de Lima, Gabriel C. B. Pereira, Marcelo V. Negrão, Rossana V. M. López, Fernanda C. Capareli, Jorge Sabbaga and Paulo Marcelo G. Hoff
A randomized trial demonstrated that capecitabine is at least as effective as fluorouracil in the adjuvant treatment of patients with locally advanced rectal cancer. However, not all patients receive all plann...
Authors: Flavius Sandra-Petrescu, Florian Herrle, Iris Burkholder, Peter Kienle and Ralf-Dieter Hofheinz
